{
    "clinical_study": {
        "@rank": "35132", 
        "arm_group": [
            {
                "arm_group_label": "Treatment sequence 1 (Group A)", 
                "arm_group_type": "Experimental", 
                "description": "Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)"
            }, 
            {
                "arm_group_label": "Treatment sequence 2 (Group B)", 
                "arm_group_type": "Experimental", 
                "description": "Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and\n      safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50\n      (BHI 50) twice daily, both in combination with metformin, in Chinese subjects with type 2\n      diabetes mellitus."
        }, 
        "brief_title": "Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 12 months\n\n          -  Currently treated with premixed human insulin 50 BID for at least 3 months prior to\n             screening visit (Visit 1)\n\n          -  Currently treated with unchanged total daily dose of at least 1500 mg metformin or\n             maximum tolerated dose at least 1000 mg/day metformin for at least 2 months prior to\n             screening visit\n\n          -  Glycosylated haemoglobin (HbA1c) 7.0% and 9.0% (both inclusive) (central laboratory)\n\n        Exclusion Criteria:\n\n          -  Treatment with any insulin secretagogue, alfa-glucosidase inhibitors,\n             thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like\n             peptide-1 (GLP-1) receptor agonists within the last 3 months prior to screening\n\n          -  Previous use of any insulin other than premixed human insulin 50 BID within 3 months\n             prior to Visit 1\n\n          -  Previous use of insulin intensification treatment (premixed insulin thrice daily,\n             basal bolus regimen, and continuous subcutaneous insulin infusion (CSII)) for more\n             than 14 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "161", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892020", 
            "org_study_id": "BIASP-4058", 
            "secondary_id": "U1111-1137-2342"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment sequence 1 (Group A)", 
                    "Treatment sequence 2 (Group B)"
                ], 
                "description": "Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.", 
                "intervention_name": "biphasic insulin aspart 50", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment sequence 1 (Group A)", 
                    "Treatment sequence 2 (Group B)"
                ], 
                "description": "Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.", 
                "intervention_name": "biphasic human insulin 50", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 20, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100034"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centre, Randomised, Open-labelled, 2-sequence, 2-period Crossover Trial to Investigate the Efficacy and Safety of Biphasic Insulin Aspart 50 (BIAsp 50) Twice Daily Versus Biphasic Human Insulin 50 (BHI 50) Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "2-hours PPG (postprandial plasma glucose) increment following a standard meal test", 
            "safety_issue": "No", 
            "time_frame": "After 4 weeks of treatment in each treatment sequence"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892020"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "-1-hour PPG increment following a standard meal test", 
                "safety_issue": "No", 
                "time_frame": "After 4 weeks of treatment in each treatment sequence"
            }, 
            {
                "measure": "-IIAUC (Incremental area under the curve) for PPG (0-2 hours) following a standard meal test", 
                "safety_issue": "No", 
                "time_frame": "After 4 weeks of treatment in each treatment sequence"
            }, 
            {
                "measure": "2-hours PPG increments over each of the 3 main meals in 8-point SMPG (self-measured plasma glucose) profile", 
                "safety_issue": "No", 
                "time_frame": "After 4 weeks of treatment in each treatment sequence"
            }, 
            {
                "measure": "The mean 2-hour PPG increments of the 3 main meals in 8-point SMPG profile", 
                "safety_issue": "No", 
                "time_frame": "After 4 weeks of treatment in each treatment sequence"
            }, 
            {
                "measure": "Incidence of hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "During 4 weeks of treatment in each treatment sequence"
            }, 
            {
                "measure": "Incidence of AEs (adverse event)", 
                "safety_issue": "No", 
                "time_frame": "During 4 weeks of treatment in each treatment sequence"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}